NS0

NS0是一种源自非分泌型小鼠骨髓瘤（nonsecreting murine myeloma）的细胞系，目前应用于生物医学研究和治疗型蛋白质的商业生产^[1]。NS0是一种胆固醇依赖性的细胞系，由NSI/1的一个亚系产生，而该亚系仅产生轻链（英语：Immunoglobulin light chain）而不会产生重链（英语：Immunoglobulin heavy chain）^[2]^[3]。

历史[编辑]

在BALB/c小鼠体内分离出会分泌IgG1的MOPC21肿瘤后，从该肿瘤中分离出P3K细胞，并且发展成289-16细胞和P3-X63细胞。289-16细胞仅分泌轻链而不会分泌重链，并且被重命名为NSI/1。从该细胞系中分离出克隆，并鉴定出其为新的非分泌型细胞系，命名其为NS0/1^[2]^[4]。

用途[编辑]

作为骨髓瘤细胞的NS0细胞是具有天然抗体的悬浮细胞，并且拥有淋巴母细胞（英语：Lymphoblast）形态。基因扩增（英语：Gene amplification）通常使用经GS转染的NS0细胞进行选择，以产生细胞系^[5]。GS-NS0是一种异源哺乳动物表达（英语：Heterologous expression）系统，可以表达重组蛋白。使用NS0细胞可以产生达利珠单抗（英语：Daclizumab）和依库珠单抗（英语：Eculizumab）等具治疗作用的抗体产品^[6]。

参考资料[编辑]

^ Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效链接]}
^ ^2.0 ^2.1 Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效链接]}
^ Sato, JD; Cao, HT; Kayada, Y; Cabot, MC; Sato, GH; Okamoto, T; Welsh, CJ. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium.. In vitro cellular & developmental biology : journal of the Tissue Culture Association. 1988-12, 24 (12): 1223–8 [2020-01-06]. PMID 3209588. doi:10.1007/bf02624194. ^{[永久失效链接]}
^ Galfrè, G; Milstein, C. Preparation of monoclonal antibodies: strategies and procedures.. Methods in enzymology. 1981, 73 (Pt B): 3–46 [2020-01-06]. PMID 7300683. doi:10.1016/0076-6879(81)73054-4. ^{[永久失效链接]}
^ Barnes, LM; Bentley, CM; Dickson, AJ. Characterization of the stability of recombinant protein production in the GS-NS0 expression system.. Biotechnology and bioengineering. 2001-05-20, 73 (4): 261–70 [2020-01-06]. PMID 11283909. doi:10.1002/bit.1059. ^{[永久失效链接]}
^ Wurm, FM. Production of recombinant protein therapeutics in cultivated mammalian cells.. Nature biotechnology. 2004-11, 22 (11): 1393–8 [2020-01-06]. PMID 15529164. doi:10.1038/nbt1026. ^{[永久失效链接]}

外部链接[编辑]

Cellosaurus entry for NS0（页面存档备份，存于互联网档案馆）

[1] Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效链接]}

[a-2] 2.0 ^2.1 Barnes, LM; Bentley, CM; Dickson, AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system.. Cytotechnology. 2000-02, 32 (2): 109–23 [2020-01-06]. PMID 19002973. doi:10.1023/A:1008170710003. ^{[永久失效链接]}

[3] Sato, JD; Cao, HT; Kayada, Y; Cabot, MC; Sato, GH; Okamoto, T; Welsh, CJ. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium.. In vitro cellular & developmental biology : journal of the Tissue Culture Association. 1988-12, 24 (12): 1223–8 [2020-01-06]. PMID 3209588. doi:10.1007/bf02624194. ^{[永久失效链接]}

[4] Galfrè, G; Milstein, C. Preparation of monoclonal antibodies: strategies and procedures.. Methods in enzymology. 1981, 73 (Pt B): 3–46 [2020-01-06]. PMID 7300683. doi:10.1016/0076-6879(81)73054-4. ^{[永久失效链接]}

[5] Barnes, LM; Bentley, CM; Dickson, AJ. Characterization of the stability of recombinant protein production in the GS-NS0 expression system.. Biotechnology and bioengineering. 2001-05-20, 73 (4): 261–70 [2020-01-06]. PMID 11283909. doi:10.1002/bit.1059. ^{[永久失效链接]}

[6] Wurm, FM. Production of recombinant protein therapeutics in cultivated mammalian cells.. Nature biotechnology. 2004-11, 22 (11): 1393–8 [2020-01-06]. PMID 15529164. doi:10.1038/nbt1026. ^{[永久失效链接]}

[1]

[2]

[3]

[4]

[5]

[6]